Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients DOI Creative Commons
Maurizio Salvadori, Alberto Rosati, Giuseppina Rosso

et al.

Transplantology, Journal Year: 2024, Volume and Issue: 5(3), P. 224 - 233

Published: Sept. 18, 2024

Sodium glucose cotransporter type 2 inhibitors are a new class of drugs that act on the cardiovascular system, kidneys and metabolism in multiple ways. Indeed, even though their principal action involves transport sodium convoluted distal tubule, they have actions, such as antifibrotic endothelial protective effects. Their mechanism consists loss glucose. Therefore, affect blood pressure metabolism. first use was diabetic general population; later, some studies documented activity nondiabetic population heart failure chronic kidney disease patients. Only recent years several small efficacy these transplant patients; relatively large rare, very recent, open routes for development drugs.

Language: Английский

SGLT2 inhibitors: Beyond glycemic control DOI Creative Commons
Irtiza Hasan,

Tasnuva Rashid,

Vishal Jaikaransingh

et al.

Journal of Clinical & Translational Endocrinology, Journal Year: 2024, Volume and Issue: 35, P. 100335 - 100335

Published: March 1, 2024

Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type diabetes mellitus (DM). Notably, emerging reports drawn attention potential positive impacts SGLT2 inhibitors nondiabetic patients. In an effort delve into this phenomenon, comprehensive systematic literature review spanning PubMed (NLM), Medline (Ovid), and Cochrane Library, covering publications from 2000 2024 was undertaken. This encompassed twenty-six control (RCTs) involving 35,317 participants. The findings unveiled multifaceted role for showcasing their ability enhance metabolic yield cardioprotective effects through reduction cardiovascular death (CVD) hospitalization related heart failure (HF). Additionally, renalprotective effect observed, evidenced by slowdown chronic kidney disease (CKD) progression decrease albuminuria. Importantly, these benefits were coupled acceptable safety profile. also points various biological plausibility underlying mechanistic pathways, offering insights association between outcomes individuals. Current research trends indicate continual exploration additional in. Nevertheless, further is imperative fully elucidate mechanisms long-term associated use inhibitors.

Language: Английский

Citations

14
SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART DOI Creative Commons
H C Rosen, Moman A. Mohammad, Tomas Jernberg

et al.

The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 45, P. 101032 - 101032

Published: Aug. 23, 2024

SummaryBackgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce rates of heart failure hospitalisations and cardiovascular death in patients with type diabetes prior disease. We hypothesised that SGLT2 could provide benefits the post-myocardial infarction setting. aimed investigate outcomes inhibitor therapy mellitus after myocardial a Swedish nationwide registry.MethodsWe included all surviving 1 acute from January 1, 2018 December 31, 2021. Patients were if they discharged an estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 Web-system for Enhancement Development Evidence-based care Heart disease Evaluated According Recommended Therapies (SWEDEHEART) registry. identified or without prescription 120 days before within three discharge cardiac unit. The primary outcome measure was composite first hospitalisation one year analysed using adjusted Cox regression.FindingsA total 11,271 included. Of these, 2498 (22.2%) received treatment. who prescribed younger, more often presented STEMI had worse left ventricular ejection fraction at index hospitalisation. use associated lower (hazard ratio (HR) 0.70 (95% confidence interval (CI) 0.59–0.82).InterpretationTreatment events.FundingThis work supported by Hjärt-Lungfonden, Vetenskapsrådet, Knut Alice Wallenberg Foundation, ALF, Bundy Academy, Skåne University Hospital funds.

Language: Английский

Citations

6
SGLT inhibitors for improving Healthspan and lifespan DOI Open Access
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe

et al.

Progress in Cardiovascular Diseases, Journal Year: 2023, Volume and Issue: 81, P. 2 - 9

Published: Oct. 17, 2023

Language: Английский

Citations

15
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review DOI Open Access

Liana Iordan,

Laura Gaiţă, Romulus Timar

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7057 - 7057

Published: June 27, 2024

Chronic kidney disease (CKD) is a noncommunicable condition that has become major healthcare burden across the globe, often underdiagnosed and associated with low awareness. The main cause leads to development of renal impairment diabetes mellitus and, in contrast other chronic complications such as retinopathy or neuropathy, it been suggested intensive glycemic control not sufficient preventing diabetic disease. Nevertheless, novel class antidiabetic agents, sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown multiple renoprotective properties range from metabolic hemodynamic direct effects, impact on reducing risk occurrence progression CKD. Thus, this review aims summarize current knowledge regarding mechanisms SGLT2i offer new perspective innovative antihyperglycemic drugs proven pleiotropic beneficial effects that, after decades no significant progress prevention delaying decline function, start era management patients

Language: Английский

Citations

5
C3G and Ig-MPGN—treatment standard DOI Creative Commons
Marina Noris, Giuseppe Remuzzi

Nephrology Dialysis Transplantation, Journal Year: 2023, Volume and Issue: 39(2), P. 202 - 214

Published: Aug. 21, 2023

ABSTRACT Among the broad spectrum of membranoproliferative glomerulonephritis (MPGN), immunofluorescence distinguishes C3 glomerulopathy (C3G), with predominant deposits, and immunoglobulin-associated MPGN (Ig-MPGN), combined Ig. However, there are several intersections between C3G Ig-MPGN. Primary Ig-MPGN share same prevalence low serum levels abnormalities alternative pathway complement, patients who present a bioptic pattern at onset may show in subsequent biopsy. There is no specific therapy for primary prognosis unfavourable. The only recommended indications inhibitors renin–angiotensin system, lipid-lowering agents other renoprotective agents. drugs used currently, such as corticosteroids mycophenolate mofetil, often ineffective. anti-C5 monoclonal antibody eculizumab has been tested patients, mixed results. One reason uncertainty extremely variable clinical course, most likely reflecting heterogeneous pathogenesis. An unsupervised clustering analysis that included histologic, biochemical, genetic data available identified four clusters characterized by pathogenic mechanisms. This approach facilitate accurate diagnosis development targeted therapies. Several trials ongoing targeting different molecules complement cascade, however it important to consider which component cascade be appropriate each patient. We review current standards treatment discuss novel developments pathophysiology, diagnosis, outcome prediction management

Language: Английский

Citations

12
Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side DOI Open Access
Aly M. Abdelrahman, Alaa S. Awad, Emaad M. Abdel‐Rahman

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(4), P. 956 - 956

Published: Feb. 7, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials emerging supporting a role irrespective diabetic status pointing towards that have other mechanisms actions beyond blood sugar control. In this review, we will shed light on group medications act as in non-diabetics focusing pre-clinical clinical data highlighting mechanism renoprotection effects non-diabetic kidneys.

Language: Английский

Citations

4
Canagliflozin Inhibits Hedgehog Interacting Protein (Hhip) Induction of Tubulopathy in Diabetic Akita Mice DOI

Shiao‐Ying Chang,

Min-Chun Liao,

Kana N. Miyata

et al.

Translational research, Journal Year: 2025, Volume and Issue: 277, P. 13 - 26

Published: Jan. 5, 2025

Language: Английский

Citations

0
Effect of SGLT2 inhibition on salt-induced hypertension in female Dahl SS rats DOI Creative Commons
Olha Kravtsova, Vladislav Levchenko, Christine A. Klemens

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Nov. 6, 2023

Abstract Sodium-glucose co-transporters (SGLTs) in the kidneys play a pivotal role glucose reabsorption. Several clinical and population-based studies revealed beneficial effects of SGLT2 inhibition on hypertension. Recent work from our lab provided significant new insight into non-diabetic model salt-sensitive hypertension, Dahl (SS) rats. Dapagliflozin (Dapa) blunted development salt-induced hypertension by causing glucosuria natriuresis without changes Renin–Angiotensin–Aldosterone System. However, initial study used male SS rats only, effect inhibitors females has not been studied. Therefore, goal this was to determine whether alters blood pressure kidney function female The result showed that administration Dapa for 3 weeks prevented progression rats, similar its Diuresis excretion were significantly increased Dapa-treated also attenuated but heart fibrosis. Despite pressure, treatment caused minor electrolyte balance no weights observed. Our data suggest blunts independent sex.

Language: Английский

Citations

8
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data DOI Creative Commons

Jorge Balaguer Germán,

Marcelino Cortés, Carlos Rodríguez López

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1507 - 1507

Published: July 7, 2024

(1) Background: The validation of new lines therapy for the elderly is required due to progressive ageing world population and scarce evidence in patients with HF reduced ejection fraction (HFrEF). purpose our study analyze effect SGLT2 inhibitors (SGLT2i) this subgroup patients. (2) Methods: A single-center, real-world observational was performed. We consecutively enrolled all aged ≥ 75 years diagnosed HFrEF treatment SGLT2i, considered theoretical indications. (3) Results: total 364 were recruited, a mean age 84.1 years. At inclusion, LVEF 29.8%. Median follow-up 33 months, there 122 deaths. 55 under SGLT2i treatment. multivariate Cox logistic regression test all-cause mortality performed, only (HR 0.39 [0.19–0.82]) glomerular filtration rate 0.98 [0.98–0.99]) proved be protective factors. In parallel, we conducted propensity-score-matched analysis, where significant reduction associated use 0.39, [0.16–0.97]). (4) Conclusions: Treatment lower mortality. Our data show that could improve prognosis study.

Language: Английский

Citations

2
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis DOI
Chu-Hsuan Shiau,

Li-Yun Tsau,

Chih‐Chin Kao

et al.

International Urology and Nephrology, Journal Year: 2023, Volume and Issue: 56(4), P. 1359 - 1381

Published: Sept. 26, 2023

Language: Английский

Citations

6